67 FR 86 pg. 22414 - Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Application Concerning a Method of Making a Vaccine for Anthrax
Type: NOTICEVolume: 67Number: 86Page: 22414
FR document: [FR Doc. 02-11072 Filed 5-2-02; 8:45 am]
Agency: Defense Department
Sub Agency: Department of the Army
Official PDF Version: PDF Version
DEPARTMENT OF DEFENSE
Department of the Army
Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Application Concerning a Method of Making a Vaccine for Anthrax
AGENCY:
Department of the Army, DoD.
ACTION:
Notice.
SUMMARY:
In accordance with 37 CFR 404.6 and 404.7, announcement is made of the availability for licensing of U.S. Patent Application Serial No. 09/520,215 entitled "Method of Making a Vaccine for Anthrax," filed March 7, 2000. The United States Government, as represented by the Secretary of the Army has rights in this invention.
ADDRESSES:
Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702-5012.
FOR FURTHER INFORMATION CONTACT:
For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment, (301) 619-6664, both at telefax (301) 619-5034.
SUPPLEMENTARY INFORMATION:
A method of making a vaccine from a protective antigen. The protective antigen is useful against Bacillus anthracis. The protective antigen is produced by an asporogenic organism, which overproduces the desired antigen. The asporogenic organism is a recombinant asporogenic B. anthracis. The recombinant asporogenic B. anthracis was derived from a ? Sterne-1(pPA102) strain of bacteria and binds to dye when grown on Congo Red Agar.
Luz D. Ortiz,
Army Federal Register Liaison Officer.
[FR Doc. 02-11072 Filed 5-2-02; 8:45 am]
BILLING CODE 3710-08-M